Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes
Status:
Unknown status
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The investigators are conducting a study of asthma patients who use fluticasone with
salmeterol (Advair) or any other combination of an inhaled corticosteroid (ICS) and a long
acting beta agonist (LABA) to manage their asthma symptoms.
Participants begin the study by continuing to use fluticasone with salmeterol or substituting
fluticasone with salmeterol for their current ICS/LABA medication at their regular dose or
the comparable dose(all study medications are provided) for a six-week period. Patients are
then separated into 2 groups: one group is asked to use fluticasone (Flovent), the other to
use fluticasone with salmeterol , twice daily over a 16-week period (patients will need to be
seen monthly during this time). Neither study personnel nor patients will know which drug is
being used.
Patients are also asked to use a peak flow meter and record their daily results on a form,
along with the number of puffs they use of their rescue inhaler each day. They also record
any changes in asthma medications and information on any asthma episodes.
The investigators hypothesize that there are certain patients with asthma who will do better
when a long acting beta agonist is removed from their maintenance asthma medications.
Phase:
N/A
Details
Lead Sponsor:
Columbia University
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance